Overview: Ganglioside GD1a IgM TestIntroduction: The Ganglioside GD1a IgM Test detects IgM antibodies to GD1a to diagnose acute neurological disorders, causing weakness or numbness. Aligned with 2023 AAN guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected neurological disorders.
Other Names: GD1a IgM Assay, Anti-GD1a IgM Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: GD1a IgM testing began in the 1990s with neurological research. Immunoassays emerged in the 2000s, improving accuracy for acute disorders.
Purpose: Diagnoses acute neurological disorders, guides treatment, and monitors GD1a IgM antibodies in patients with weakness or numbness.
Test Parameters: 1. GD1a IgM
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like weakness or numbness, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document weakness, numbness, or history of neurological disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for autoimmune therapy.
Procedural Considerations: Uses an immunoassay to detect GD1a IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis or improper storage can affect results. Other autoimmune conditions may cause cross-reactivity.
Clinical Significance: Positive GD1a IgM antibodies suggest acute neurological disorders, prompting treatment. Negative results may require further testing.
Specialist Consultation: Consult a neurologist for result interpretation.
Additional Supporting Tests: EMG, nerve conduction studies, or other ganglioside tests to confirm neurological disorders.
Test Limitations: False positives may occur in other autoimmune conditions. Results require clinical correlation.
References: AAN Neurological Guidelines, 2023; Neurology, Willison HJ, 2022.
